Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation

被引:158
作者
Nakase, Ikuhiko [1 ,3 ]
Lai, Henry [2 ]
Singh, Narendra P. [2 ]
Sasaki, Tomikazu [1 ]
机构
[1] Univ Washington, Dept Chem, Seattle, WA 98195 USA
[2] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA
[3] Kyoto Univ, Chem Res Inst, Kyoto 6110011, Japan
关键词
artemisinin; transferrin; conjugation; anticancer property; cytotoxicity;
D O I
10.1016/j.ijpharm.2007.09.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Artemisinin and its derivatives are well known antimalaria drugs and particularly useful for the treatment of infection of Plasmodium falciparum malaria parasites resistant to traditional antimalarials. Artemisinin has an endoperoxide bridge that is activated by intraparasitic heme-iron to form free radicals, which kill malaria parasites by alkylating biomolecules. In recent years, there are many reports of anticancer activities of artemisinins both in vitro and in vivo. Artemisinins have inhibitory effects on cancer cell growth, including many drug- and radiation-resistant cancer cell lines. The cytotoxic effect of artemisinin is specific to cancer cells because most cancer cells express a high concentration of transferrin receptors on cell surface and have higher iron ion influx than normal cells via transferrin mechanism. In addition, some artemisinin analogs have been shown to have antiangiogenesis activity. Artemisinin tagged to transferrin via carbohydrate chain has also been shown to have high potency and specificity against cancer cells. The conjugation enables targeted delivery of artemisinin into cancer cells. In this review, we discuss the anticancer activities and mechanisms of action of artemisinins and the transferrin-conjugate. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:28 / 33
页数:6
相关论文
共 46 条
[1]   Dealing with iron: Common structural principles in proteins that transport iron and heme [J].
Baker, HM ;
Anderson, BF ;
Baker, EN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3579-3583
[2]  
Berger TG, 2005, ONCOL REP, V14, P1599
[3]  
CASTANEDA VL, 1991, LEUKEMIA, V5, P142
[4]   Antimalarial dihydroartemisinin also inhibits angiogenesis [J].
Chen, HH ;
Zhou, HJ ;
Wang, WQ ;
Wu, GD .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (05) :423-432
[5]   Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1 [J].
Chen, HH ;
Zhou, HJ ;
Wu, GD ;
Lou, XE .
PHARMACOLOGY, 2004, 71 (01) :1-9
[6]   Structure of the human transferrin receptor-transferrin complex [J].
Cheng, Y ;
Zak, O ;
Alsen, P ;
Harrison, SC ;
Walz, T .
CELL, 2004, 116 (04) :565-576
[7]   Kinetics of iron-mediated artemisinin degradation: Effect of solvent composition and iron salt [J].
Creek, DJ ;
Chiu, FCK ;
Prankerd, RJ ;
Charman, SA ;
Charman, WN .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (08) :1820-1829
[8]  
DasGupta A, 1996, INDIAN J MED RES, V104, P226
[9]   Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate [J].
Dell'Eva, R ;
Pfeffer, U ;
Vené, R ;
Anfosso, L ;
Forlani, A ;
Albini, A ;
Efferth, T .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (12) :2359-2366
[10]  
Dhingra V, 1999, LIFE SCI, V66, P279, DOI 10.1016/S0024-3205(99)00356-2